ArticleBMC public health2026
Prevalence and comorbidity burden of clinical obesity in US adults.
Article in BMC public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundThis study aimed to estimate the prevalence and comorbidity burden of clinical obesity among US adults.
methodsAnalyzing data from 53,333 US adults (NHANES, 1999–2018), we stratified participants into no obesity, preclinical obesity, and clinical obesity based on BMI, waist circumference, and presence of organ dysfunction or functional limitations. Mortality risks were assessed via survey-weighted Cox proportional hazards regression, Fine-Gray subdistribution hazard model, and Kaplan–Meier curves. Latent class analysis (LCA) identified distinct comorbidity clusters.
findingsOverall obesity prevalence rose from 46.7% to 61.7%, with clinical obesity (from 34.6% to 46.6%) constituting the dominant type. Clinical obesity was associated with significantly higher risks of all-cause (HR 1.46, 95% CI 1.29–1.66) and cardiovascular (HR 1.65, 95% CI 1.29–2.10) mortality versus preclinical obesity. Within clinical obesity, individuals with ≥ 5 comorbidities had an increased all-cause mortality 3.0-fold (25.4 vs 7.8 per 1000 person-years) and cardiovascular mortality 3.4-fold (5.1 vs 1.6 per 1000 person-years) compared to a single comorbidity. LCA revealed three distinct comorbidity clusters with prognostic heterogeneity; the renal dysfunction-dominant cluster exhibited the poorest survival.
conclusionThe expanding US obesity epidemic is predominantly characterized by a growing burden of high-risk clinical obesity, signifying a shift towards more severe disease phenotypes. Accurate comorbidity quantification in clinical obesity is crucial for refining prognostic assessment and optimizing treatment strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.